“Everyone at the company is here because we want to make a difference. We take this very personally, and we are passionate about enabling people on the frontline by giving them the tools to seamlessly and easily assess the cognitive state of a healthy appearing individual.”
- Dana Penney, Co-Founder
DCT was founded in 2015 with the goal of bringing to market easy to administer and non-invasive tests to detect presymptomatic cognitive impairment. Based on over 10 years of research and development at Lahey Hospital & Medical Center and MIT, our patented technology is proven to deliver accurate and objective indicators of cognitive function and is poised to make a significant impact on the medical community.
Randall Davis, Co-Founder, is a Professor of Computer Science at the Massachusetts Institute of Technology, where he works on intelligent multimodal interaction and systems for engineering design. He has also been active in the area of intellectual property and software, serving on a number of government studies and acting as an adviser to the court in legal cases. He received his undergraduate degree from Dartmouth College and his Ph.D. from Stanford University. In 1990, he was named a founding fellow of the American Association for Artificial Intelligence and served as president of the association from 1995-1997. From 2012-2014 he served as Associate Director of MIT's CSAIL.
Dana L. Penney, Co-Founder, is the Director of Neuropsychology at Lahey Hospital and Medical Center, and Assistant Clinical Professor of Neurology, Tufts University School of Medicine. She trained in clinical neuropsychology at the West Haven VA Medical Center (1985-1986) and received her doctorate in Psychology at the University of Rhode Island in 1988. Her clinical interests are in Mild Cognitive Impairment disorder, the dementias, and the surgical treatment of neurological disorders such as Epilepsy and Parkinson’s Disease. Her clinical work provides the inspiration and foundation for her research which centers on the detection and measurement of the very earliest possible manifestations of cognitive change, and the development of novel assessment tools.
Philip Cooper, Co-Founder, Chairman, and CEO, has 30 years of experience in investment management and private equity as an entrepreneur, principal investor, fund investor, and secondary investor. He advises investment firms and fiduciary Investors on investment policy, governance, strategy and tactics including asset allocation, risk management and alternative investments. He is the co-holder of several US Patents in investment technology.
In addition to DCT, Phil is currently a co-founder of Nautical Wines LLC, which imports fine wines into China, and Natural Ships Inc., which is developing a new design for low pollution efficient natural gas powered cargo ships. Phil is Senior Partner of RSTP, a growth equity investor in tech based companies; a Special Advisor to the WAVE private equity fund, a growth investor in emerging industrial companies; on the Advisory Board of RCP Advisors, a major private equity firm in Fund of Funds, Secondary and Co-Investing; the President of Cambridge Concentus Orchestra; and a Board member of Boston Baroque Orchestra. He is a member of the Children’s Hospital (Boston) Endowment Investment Committee. Phil is also the former Vice Chairman of the Forsyth Medical Institute.
In 1996 Phil conceived, founded, and led the Goldman Sachs Private Equity Group to over $11 billion in assets and international prominence. While at Goldman Sachs, he served on the Goldman Sachs Asset Management Risk Committee, Operating Committee, and Technology Committee. He retired as a Goldman Sachs Partner in 2004. Phil received his BS from Syracuse University and an MS in Management from MIT Sloan, where he was an Alfred Sloan Fellow and is currently a Senior Lecturer in Finance and a member of the MIT Sloan School Finance Advisory Committee.
Bob Brady, PhD
Principal Software Engineer
VP, Regulatory Affairs and Quality Assurance
Senior VP, Clinical Division
Antonia Holway, PhD
Senior VP, Research Division
Bob Knox Jr.
VP, Artificial Intelligence and Analytics
Rhoda Au, PhD
Roberta Clarke, DBA
Steven Kanner, MD
Bruce Musicus, PhD
Al Oppenheim, PhD
John Richert, MD
Stacie Weninger, PhD
John Richert, Advisor, is a consultant with Richert Partners. He received his BA from Cornell University and MD from the University of Rochester. After his residency in Neurology at the Mayo Clinic, he was an MS Society-sponsored post-doctoral fellow in the Myelin Chemistry Section at NIH and then spent two additional years in NIH’s Neuroimmunology Branch. He spent 25 years in the Neurology Department at Georgetown University Medical School, during the last seven of which he also served as Chair of the Department of Microbiology and Immunology. His research interests included abnormal gene expression in the immune systems of people with MS and clinical trials of new therapeutic agents in MS. He also served on the Board of Directors of Georgetown University Hospital and founded their Multiple Sclerosis Clinic. He then served for five years as the Executive Vice President for Research & Clinical Programs at the National Multiple Sclerosis Society in New York. He then moved to Cambridge, MA with Biogen, Inc., where he served in various capacities, including as Program Executive for the interferon and anti-LINGO programs and as VP for Neurology in the Medical Affairs Dept. He has authored and co-authored over 110 journal articles and is listed in Who’s Who in America, Who’s Who in the World, and America’s Top Doctors.
Alan V. Oppenheim, Founding Senior Advisor, is a principal investigator in the Research Laboratory of Electronics (RLE) at the Massachusetts Institute of Technology (MIT). He received the S.B. and S.M. degrees in 1961 and the Sc.D. degree in 1964, all in electrical engineering, from the Massachusetts Institute of Technology. He is also the recipient of an honorary doctorate from Tel Aviv University. He is currently Ford Professor of Engineering in the Department of Electrical Engineering and Computer Science at MIT. His research interests are in the general area of signal processing and its applications. He is coauthor of widely used textbooks and editor of several advanced books on signal processing. Dr. Oppenheim is a member of the National Academy of Engineering, a Life Fellow of the IEEE, a member of Sigma Xi and Eta Kappa Nu. He has won many awards for both outstanding research and excellence in teaching.
Rhoda Au, Founding Senior Advisor, is Professor of Neurology at Boston University School of Medicine and a Senior Investigator and Director of Neuropsychology for the Framingham Heart Study. Her research interests are currently focused on cognitive aging and dementia, including early neuropsychological indicators of disease. She received her undergraduate degree from Pomona College and her Ph.D. from the University of California, Riverside. In addition she has an MBA from Boston University and is working on developing a translational research and technology innovation program with a number of Hong Kong and Mainland China institutions focused on a joint Aging Well Initiative that includes the development of a Chinese national cohort study and entrepreneurial business opportunities.
Steven Kanner, Advisor, earned his AB from Harvard College in 1965 and his MD from Harvard Medical School in 1969. He interned in medicine at Mount Sinai Hospital in New York and completed his medical residency at Johns Hopkins in Baltimore, where he was a Clinical Scholar of the Robert Wood Johnson Foundation. He is a diplomate of the American Board of Internal Medicine. Because of his experiences working in the US Public Health Service after internship, and his concerns about the adequacy of our health care system, Dr. Kanner earned a masters in management at MIT’s Sloan School of Management in 1974. He now runs Orchard Health Care, a small practice affiliated with Beth Israel Deaconess Medical Center.
Robert Knox, Board Member, was a founder of Prudential Equity Investors in 1984 and was among the original founding principals of Cornerstone Equity Investors in 1996. Mr. Knox has served on the boards of over 25 public and private companies. Mr. Knox is the Chairman of the Board of Trustees of Boston University, where he received his B.A. and M.B.A. degrees.
Roberta (Bobbi) Clarke, Advisor, is an Associate Professor at Boston University's School of Management and was one of the first experts in the field of health care marketing. Dr. Clarke serves on the Editorial Review Boards of Health Services Management Research and Strategies for Healthcare Excellence, and formerly on the editorial review boards of the Journal of Health Care Marketing and Health Care Management Review. She has been the faculty director of the Boston University Biotechnology Association since its inception in 2002. Professor Clarke received her MBA and Doctorate from the Harvard Graduate School of Business Administration.
Bruce Musicus, Advisor, was previously the Chief Technology Officer and a founder of Parlance Corp., which provides a speech-enabled auto-attendant telephony service. Prior to Parlance, he was CTO of BBN Speech Processing Group, the Director of Development of BBN HARK Systems, and an Associate Professor in MIT's Department of Electrical Engineering and Computer Science. Dr. Musicus is a leading expert in iterative processing algorithms and has worked extensively on a variety of technologies including word spotting, speech recognition, image recognition, finite element simulations, matched filter detectors, sonar processors, VLSI architectures, stochastic filtering, microprocessor design, computational structures, real-time control, and robust software. He holds patents in fault tolerant architectures, time-scale modification of signals, and programmable real-time signal processors. Dr. Musicus received his SB from Harvard University. He received his MS, EE, and PhD degrees in Electrical Engineering and Computer Science from MIT.
Bill Romeo, is a passionate and seasoned financial executive with over 25 years of strategic, financial and operational management experience, Bill has successfully navigated several companies through rapid growth. Bill’s broad experience includes executive leadership with high growth and commercially driven Healthcare Technology and Life Sciences companies. Bill is recognized for scaling, managing and leading rapidly growing technology companies. He has a successful history of financing via public/private equity transactions, fundraising and debt structuring. He has also been a key executive in the development of strategic and operational goals for several organizations, and has implemented strategies and metrics to drive performance.
Stacie Weninger is the Executive Director of the F-Prime Biomedical Research Initiative. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, Dr. Weninger was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children’s Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.
Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina, Chapel Hill. She currently chairs the Collaboration for Alzheimer’s Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; serves as a member of the Board of Directors for Denali Therapeutics, Zebra Medical Technologies, Aratome, BRI-Tolan, Q-State Biosciences, and Digital Cognition Technologies; and she previously served as a member of the Board of Directors for Annexon Biosciences, BRI-Alzan, and Inscopix.
Don Hardison has more than 30 years of executive leadership experience in both emerging and Fortune 500 companies, including roles as CEO and COO, as well as a board member. Most recently, Don served as president, CEO, and director of Good Start Genetics, Inc. He also served in a similar capacity at EXACT Sciences Corp., where he was actively involved in taking the company public and was primarily responsible for a novel multi-million dollar strategic partnership with Laboratory Corporation of America (LabCorp). He has extensive experience in diagnostic laboratory management, sales, marketing, strategy, operations and broad reimbursement expertise.
Don also has held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham Corp., where he built a strong track record in strategy development, team building, and market planning and execution.
Nancy Briefs is an experienced medical technology entrepreneur with over 30 years in the industry. She has held management positions at five prior med-tech startups, four of which resulted in a liquidity event. She was awarded the Ernst & Young New England Entrepreneur of the Year Award for Emerging Companies in 2003, the NH Biotech Council "Spirit Award" in 2009 and the "Leadership & Inspiration: Award from Women Entrepreneurs in Science and Technology in 2010.
Nancy currently serves on the Boards of MyndBlue and HealthHelm. An entrepreneur inventor, Nancy is listed on seven issued and two pending US patents. Nancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University.